KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $71.6 million.

  • Alnylam Pharmaceuticals' Share-based Compensation fell 2183.75% to $71.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $348.2 million, marking a year-over-year increase of 2798.8%. This contributed to the annual value of $348.2 million for FY2025, which is 2798.8% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Share-based Compensation stood at $71.6 million, which was down 2183.75% from $108.2 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Share-based Compensation high stood at $128.1 million for Q3 2022, and its period low was $29.3 million during Q1 2022.
  • Its 5-year average for Share-based Compensation is $61.9 million, with a median of $50.7 million in 2021.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Share-based Compensation soared by 28396.62% in 2022, and later crashed by 5009.52% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Share-based Compensation stood at $44.6 million in 2021, then decreased by 4.07% to $42.8 million in 2022, then decreased by 1.81% to $42.0 million in 2023, then soared by 118.23% to $91.6 million in 2024, then decreased by 21.84% to $71.6 million in 2025.
  • Its last three reported values are $71.6 million in Q4 2025, $108.2 million for Q3 2025, and $111.7 million during Q2 2025.